The bifunctional folate enzyme methylene tetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2) is widely overexpressed in cancer, possesses a highly cancer‐specific expression profile, and has been validated extensively as a promising anticancer target in various tumor types [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23]. This evidence concerns the gene MTHFD2 and cancer.